<?xml version='1.0' encoding='utf-8'?>
<document id="31430908"><sentence text="In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters." /><sentence text="APINACA (known as AKB48, N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide), an indazole carboxamide synthetic cannabinoid, has been used worldwide as a new psychoactive substance"><entity charOffset="25-75" id="DDI-PubMed.31430908.s2.e0" text="N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide" /><entity charOffset="81-101" id="DDI-PubMed.31430908.s2.e1" text="indazole carboxamide" /><entity charOffset="112-123" id="DDI-PubMed.31430908.s2.e2" text="cannabinoid" /><pair ddi="false" e1="DDI-PubMed.31430908.s2.e0" e2="DDI-PubMed.31430908.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31430908.s2.e0" e2="DDI-PubMed.31430908.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31430908.s2.e0" e2="DDI-PubMed.31430908.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31430908.s2.e1" e2="DDI-PubMed.31430908.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31430908.s2.e1" e2="DDI-PubMed.31430908.s2.e2" /></sentence><sentence text=" Drug abusers take various drugs concomitantly, and therefore, it is necessary to characterize the potential of APINACA-induced drug-drug interactions due to the modulation of drug-metabolizing enzymes and transporters" /><sentence text=" In this study, the inhibitory effects of APINACA on eight major human cytochrome P450s (CYPs) and six uridine 5'-diphospho-glucuronosyltransferases (UGTs) in human liver microsomes, as well as on the transport activities of six solute carrier transporters and two efflux transporters in transporter-overexpressed cells, were investigated" /><sentence text=" APINACA exhibited time-dependent inhibition of CYP3A4-mediated midazolam 1'-hydroxylation (Ki, 4" /><sentence text="5 µM; kinact, 0" /><sentence text="04686 min-1) and noncompetitive inhibition of UGT1A9-mediated mycophenolic acid glucuronidation (Ki, 5"><entity charOffset="62-79" id="DDI-PubMed.31430908.s7.e0" text="mycophenolic acid" /></sentence><sentence text="9 µM)" /><sentence text=" APINACA did not significantly inhibit the CYPs 1A2, 2A6, 2B6, 2C8/9/19, or 2D6 or the UGTs 1A1, 1A3, 1A4, 1A6, or 2B7 at concentrations up to 100 µM" /><sentence text=" APINACA did not significantly inhibit the transport activities of organic anion transporter (OAT)1, OAT3, organic anion transporting polypeptide (OATP)1B1, OATP1B3, organic cation transporter (OCT)1, OCT2, P-glycoprotein, or breast cancer resistance protein at concentrations up to 250 μM" /><sentence text=" These data suggest that APINACA can cause drug interactions in the clinic via the inhibition of CYP3A4 or UGT1A9 activities" /><sentence text="" /></document>